Vantage Investment Partners LLC Has $17.32 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Vantage Investment Partners LLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 4.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 29,713 shares of the company’s stock after selling 1,401 shares during the period. Eli Lilly and Company makes up 1.7% of Vantage Investment Partners LLC’s holdings, making the stock its 19th biggest holding. Vantage Investment Partners LLC’s holdings in Eli Lilly and Company were worth $17,320,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Lipe & Dalton acquired a new position in Eli Lilly and Company during the 4th quarter valued at about $26,000. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company during the 3rd quarter valued at about $27,000. Retirement Group LLC lifted its position in Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after purchasing an additional 35 shares during the period. Legacy Financial Group LLC acquired a new position in Eli Lilly and Company during the 3rd quarter valued at about $35,000. Finally, Optiver Holding B.V. acquired a new position in Eli Lilly and Company during the 3rd quarter valued at about $36,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. The Goldman Sachs Group upped their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research note on Wednesday, February 21st. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Barclays upped their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Finally, Wells Fargo & Company upped their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $728.05.

View Our Latest Analysis on LLY

Eli Lilly and Company Trading Down 2.6 %

NYSE LLY opened at $726.31 on Friday. The company has a market cap of $690.11 billion, a PE ratio of 125.23, a PEG ratio of 1.58 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 12 month low of $369.76 and a 12 month high of $800.78. The stock has a 50 day moving average of $763.96 and a 200-day moving average of $660.53.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.09 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.